3,192 results on '"Wedemeyer, Heiner"'
Search Results
152. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
153. LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score
154. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
155. Comparison of 6 tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome: A prospective, observational study.
156. Einfluss der Spezialisierung auf primäre Erfolgs- sowie Komplikationsrate bei der ERCP. Vorschlag zur Verbesserung der Qualität der ERCP.
157. Graft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction.
158. Impending HCC diagnosis in patients with cirrhosis after HCV cure features a natural killer cell signature.
159. Elevated liver enzymes in a German tertiary-care hospital: Distribution, diagnostic steps and diagnosis groups.
160. Transjugular liver biopsy and hepatic venous pressure gradient measurement in patients with and without liver cirrhosis
161. Age-specific and sex-specific risks for HCC in African-born persons with chronic hepatitis B without cirrhosis
162. Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients
163. Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss
164. Early treatment of acute or recently acquired hepatitis C: An important tool on the path to HCV elimination!
165. Neue und aktuelle Therapieoptionen bei Hepatitis D
166. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies
167. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B
168. Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study
169. EASL Recommendations on Treatment of Hepatitis C 2018
170. BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment
171. EASL Clinical Practice Guidelines on hepatitis E virus infection
172. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C
173. Die Gastroenterologie im Wandel: Herausforderungen und Chancen
174. Beeinflusst die UDCA-Therapie von PBC-Patienten inflammatorische Serumproteine?
175. Virale Hepatitiden – nach wie vor häufig und wichtig!
176. Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study
177. Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis
178. Pulmonale Komplikationen einer Lebererkrankung sicher erkennen
179. Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
180. Correction: Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers
181. Prevention of peri-interventional hypothermia during endoscopic retrograde cholangiopancreatography using a forced-air heating system
182. Fibrosis and liver inflammation are key regulators of α1-acid glycoprotein fucosylation
183. Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany
184. Joint statement in support of hepatitis C human challenge studies
185. The impact of cirrhosis on the inflammatory milieu before and long-term after hepatitis C virus elimination by direct-acting antiviral therapy
186. The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years
187. Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D
188. S1617 Elevations in Total Serum Bile Acids During Bulevirtide Treatment Show No Association With Adverse Events of Interest in Patients With Chronic Hepatitis Delta: An Integrated Safety Analysis of 48-Week Data
189. P26 Reevaluation of the Critical Flicker Frequency in Patients With Liver Cirrhosis Reveals New Perspectives of Its Diagnostic Impact in the Detection of Hepatic Encephalopathy
190. P5 Diagnosing Minimal Hepatic Encephalopathy: Comparison of 6 Frequently Used Tests
191. P24 The Diagnostic Value of Acetylcholinesterase Activity in Minimal Hepatic Encephalopathy: An Ongoing Need for Biomarkers?
192. P132 Continued treatment of early nonresponder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis delta (CHD) through week 96 leads to improvement in virologic and biochemical responses
193. P23 Impact of Alcoholic Etiology of Liver Cirrhosis Upon mHE Diagnostics
194. P12 Value of Six Minimal Hepatic Encephalopathy Tests in Predicting Clinical Outcome in Patients With Liver Cirrhosis
195. P134 Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta: results from an interim analysis of a phase 3 randomized study
196. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
197. Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis
198. Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies
199. A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection
200. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.